223Ra-dichloride response in a patient with Paget disease and bone metastases secondary to castration-resistant prostate cancer

被引:0
作者
Garcia Canamaque, Lina [1 ]
Rioja Parada, Cristina [1 ]
Garcia de la Pena, Paloma [2 ]
机构
[1] Grp HM Hosp, Hosp Madrid Sanchinarro, Ctr Integral Oncol Clara Campal CIOCC, Dept Nucl Med, C Ona,10-B Sanchinarro, Madrid 28050, Spain
[2] Grp HM Hosp, Hosp Madrid Sanchinarro, Ctr Integral Oncol Clara Campal CIOCC, Dept Rheumatol, Madrid, Spain
关键词
Ra-223-dichloride; Bone metastases; Paget disease; RADIUM-223; DICHLORIDE;
D O I
10.5301/tj.5000641
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Paget disease is commonly asymptomatic and discovered when an imaging test is performed for another clinical indication or when elevated serum alkaline phosphatase is found. Bone pain usually appears late in the disease process and is only present in a minority of patients. For diagnosis, X-ray and bone scan are the most recommended imaging methods; radionuclide imaging of the skeleton has become the standard, since it is the most sensitive test for detecting increased bone activity. For treatment, either bisphosphonates or calcitonin are recommended. Methods: We present a 74-year-old patient diagnosed with prostate cancer in 2001 who developed bone metastases concomitant with a Paget bone disease. Results: This patient received treatment with Ra-223, having stable disease in bone scan and no relevant toxicities. Conclusions: There is no clinical experience with Ra-223 and Paget disease, since it is characterized classically as a high bone turnover disease and therefore there is no rationale to administer a drug that has a high bone affinity. Nevertheless, Ra-223 is not contraindicated.
引用
收藏
页码:S53 / S55
页数:3
相关论文
共 50 条
  • [31] Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases
    Zustovich, Fable
    Fabiani, Francesca
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 91 (02) : 197 - 209
  • [32] Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
    Heidenreich, Axel
    Gillessen, Silke
    Heinrich, Daniel
    Keizman, Daniel
    O'Sullivan, Joe M.
    Carles, Joan
    Wirth, Manfred
    Miller, Kurt
    Reeves, John
    Seger, Monica
    Nilsson, Sten
    Saad, Fred
    BMC CANCER, 2019, 19 (1)
  • [33] Management of Bone Metastases fin Patients with Castration-Resistant Prostate Cancer
    Cathomas, Richard
    Bajory, Zoltan
    Bouzid, Mounira
    El Ghoneimy, Ahmed
    Gillessen, Silke
    Goncalves, Frederico
    Kacso, Gabriel
    Kramer, Gero
    Milecki, Piotr
    Pacik, Dalibor
    Tantawy, Wahid
    Lesniewski-Kmak, Krzystof
    UROLOGIA INTERNATIONALIS, 2014, 92 (04) : 377 - 386
  • [34] Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
    Uemura, Hirotsugu
    Uemura, Hiroji
    Nagamori, Satsohi
    Wakumoto, Yoshiaki
    Kimura, Go
    Kikukawa, Hiroaki
    Yokomizo, Akira
    Mizokami, Atsushi
    Kosaka, Takeo
    Masumori, Naoya
    Kawasaki, Yoshihide
    Yonese, Junji
    Nasu, Yasutomo
    Fukasawa, Satoshi
    Sugiyama, Takayuki
    Kinuya, Seigo
    Hosono, Makoto
    Yamaguchi, Iku
    Akagawa, Takashi
    Matsubara, Nobuaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (05) : 557 - 566
  • [35] Lymph Node Response in a Patient With Metastatic Castration-resistant Prostate Cancer Treated With Radium-223
    Poon, Darren M. C.
    Wong, Kenneth C. W.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : E397 - E401
  • [36] Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2therapy
    Sraieb, Miriam
    Hirmas, Nader
    Conrad, Rupert
    Marinova, Milka
    Essler, Markus
    Herrmann, Ken
    Ahmadzadehfar, Hojjat
    MEDICINE, 2020, 99 (38)
  • [37] Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer
    Parimi, Sunil
    Bondy, Suraya
    Tsang, Erica
    McKenzie, Michael Ross
    Bachand, Francois
    Aparicio, Maria
    Duncan, Graeme
    Sunderland, Katherine
    Olson, Robert Anton
    Pai, Howard Huaihan
    Alexander, Abraham Skaria
    LaPointe, Vincent
    Chi, Kim N.
    Tyldesley, Scott
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2019, 13 (10): : E311 - E316
  • [38] Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases
    Yamamoto, Yoshiyuki
    Okuda, Yohei
    Kanaki, Tomohiro
    Tanaka, Ryo
    Nagahara, Akira
    Nakai, Yasutomo
    Nakayama, Masashi
    Kakimoto, Ken-ichi
    Nishimura, Kazuo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 192 - 198
  • [39] Radium-223 for the treatment of castration-resistant prostate cancer
    El-Amm, Joelle
    Aragon-Ching, Jeanny B.
    ONCOTARGETS AND THERAPY, 2015, 8 : 1103 - 1109
  • [40] RADIUM 223 FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Miranda, Jesus
    Vinal, David
    Pinto, Alvaro
    ARCHIVOS ESPANOLES DE UROLOGIA, 2019, 72 (05): : 500 - 507